ATE446744T1 - Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit - Google Patents
Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheitInfo
- Publication number
- ATE446744T1 ATE446744T1 AT04764129T AT04764129T ATE446744T1 AT E446744 T1 ATE446744 T1 AT E446744T1 AT 04764129 T AT04764129 T AT 04764129T AT 04764129 T AT04764129 T AT 04764129T AT E446744 T1 ATE446744 T1 AT E446744T1
- Authority
- AT
- Austria
- Prior art keywords
- parkinson
- treatment
- disease
- combinations
- active ingredients
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 abstract 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 abstract 1
- 239000000150 Sympathomimetic Substances 0.000 abstract 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 229940052760 dopamine agonists Drugs 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000001975 sympathomimetic effect Effects 0.000 abstract 1
- 229940064707 sympathomimetics Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10338174A DE10338174A1 (de) | 2003-08-20 | 2003-08-20 | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| PCT/EP2004/009136 WO2005018619A1 (de) | 2003-08-20 | 2004-08-14 | Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE446744T1 true ATE446744T1 (de) | 2009-11-15 |
Family
ID=34201721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04764129T ATE446744T1 (de) | 2003-08-20 | 2004-08-14 | Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8980308B2 (enExample) |
| EP (1) | EP1656122B2 (enExample) |
| JP (2) | JP2007502795A (enExample) |
| KR (1) | KR20060065692A (enExample) |
| CN (1) | CN1832732A (enExample) |
| AT (1) | ATE446744T1 (enExample) |
| AU (1) | AU2004266063B2 (enExample) |
| BR (1) | BRPI0412054A (enExample) |
| CA (1) | CA2535063C (enExample) |
| DE (2) | DE10338174A1 (enExample) |
| DK (1) | DK1656122T4 (enExample) |
| ES (1) | ES2335771T5 (enExample) |
| IL (1) | IL173712A (enExample) |
| MX (1) | MXPA06001815A (enExample) |
| NZ (1) | NZ545593A (enExample) |
| PL (1) | PL1656122T5 (enExample) |
| PT (1) | PT1656122E (enExample) |
| RU (1) | RU2397757C2 (enExample) |
| SI (1) | SI1656122T2 (enExample) |
| WO (1) | WO2005018619A1 (enExample) |
| ZA (1) | ZA200509779B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10338174A1 (de) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| PL1907382T3 (pl) | 2005-07-26 | 2016-01-29 | Bial Portela & Ca Sa | Pochodne nitrokatecholowe jako inhibitory COMT |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| CA2678391C (en) | 2007-01-31 | 2017-01-17 | David Alexander Learmonth | Dosage regimen for comt inhibitors |
| RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
| ES2521494T3 (es) * | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
| JP2010525018A (ja) * | 2007-04-24 | 2010-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物 |
| KR20190079705A (ko) * | 2008-07-29 | 2019-07-05 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 화합물 및 그 약학적 조성물 |
| RU2701731C2 (ru) | 2009-04-01 | 2019-10-01 | Биал-Портела Энд Ка, С.А. | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения |
| KR101292768B1 (ko) * | 2010-04-23 | 2013-08-05 | 아이큐어 주식회사 | 경피 흡수 제제 |
| US9017723B2 (en) | 2010-04-30 | 2015-04-28 | Teikoku Pharma Usa, Inc. | Propynylaminoindan transdermal compositions |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON |
| WO2013070526A1 (en) | 2011-11-09 | 2013-05-16 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
| EP3604299B1 (en) | 2011-12-13 | 2023-07-26 | Bial-Portela & CA, S.A. | Chemical compound useful as intermediate for preparing a catechol-0-methyl transferase inhibitor |
| US20130197023A1 (en) * | 2012-01-27 | 2013-08-01 | California Institute Of Technology | Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors |
| NZ706590A (en) | 2012-11-02 | 2016-02-26 | Teikoku Pharma Usa Inc | Propynylaminoindan transdermal compositions |
| US10111879B2 (en) | 2013-06-27 | 2018-10-30 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| CN103622997A (zh) * | 2013-11-22 | 2014-03-12 | 内蒙古医科大学 | 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物 |
| EP2946775A1 (de) | 2014-05-20 | 2015-11-25 | LTS LOHMANN Therapie-Systeme AG | Lavendelöl enthaltendes transdermales therapeutisches System |
| JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| CN104510725B (zh) * | 2015-01-22 | 2021-04-27 | 中国药科大学 | 一种普拉克索周效透皮贴剂及其制备方法 |
| WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| WO2018067163A1 (en) * | 2016-10-07 | 2018-04-12 | Transwell Biotech Co., Ltd. | Pramipexole transdermal delivery system and uses thereof |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| AU2020258086A1 (en) | 2019-04-17 | 2021-11-11 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US20240299501A1 (en) * | 2023-03-06 | 2024-09-12 | Xygenyx Inc. | Composition and methods of treatment using transdermal hormone supplementation |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| JPH0611698B2 (ja) | 1984-12-19 | 1994-02-16 | 大正製薬株式会社 | 貼付剤 |
| US4666441A (en) * | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| DE3710966A1 (de) | 1986-04-16 | 1987-12-03 | Degussa | Synergistische kombination von amantadin und selegilin |
| EP0241809B1 (de) * | 1986-04-16 | 1990-08-08 | ASTA Pharma Aktiengesellschaft | Synergistische Kombination von Amantadin und Selegilin |
| US4877618A (en) * | 1988-03-18 | 1989-10-31 | Reed Jr Fred D | Transdermal drug delivery device |
| GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| HK1006281A1 (en) * | 1992-07-28 | 1999-02-19 | The Procter & Gamble Company | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
| US5462746A (en) * | 1992-11-02 | 1995-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
| DE4332094C2 (de) * | 1993-09-22 | 1995-09-07 | Lohmann Therapie Syst Lts | Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung |
| US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| GB9511366D0 (en) | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
| IL122484A0 (en) | 1995-06-07 | 1998-06-15 | Noven Pharma | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| DE19626621A1 (de) | 1996-07-02 | 1998-01-08 | Hexal Ag | Pflaster zur transdermalen Anwendung von Pergolid |
| US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
| JPH11209271A (ja) | 1998-01-23 | 1999-08-03 | Nitto Denko Corp | 経皮吸収製剤 |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| DE60006069T2 (de) | 1999-02-05 | 2004-07-29 | Cipla Ltd. | Topische sprays enthaltend eine filmbildende zusammensetzung |
| AU5325000A (en) | 1999-06-05 | 2000-12-28 | David Houze | Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use |
| DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| FR2798065B1 (fr) | 1999-09-02 | 2003-09-05 | Assist Publ Hopitaux De Paris | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
| JP2002097137A (ja) * | 2000-07-19 | 2002-04-02 | Junichi Sudo | パーキンソン病の予防および／または治療剤 |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| DE10066158B4 (de) | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
| US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
| DE10064453A1 (de) | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
| EP1325742A1 (en) | 2001-05-08 | 2003-07-09 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of Parkinson's disease |
| ATE251901T1 (de) | 2001-05-08 | 2003-11-15 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
-
2003
- 2003-08-20 DE DE10338174A patent/DE10338174A1/de not_active Withdrawn
-
2004
- 2004-08-14 WO PCT/EP2004/009136 patent/WO2005018619A1/de not_active Ceased
- 2004-08-14 DK DK04764129.5T patent/DK1656122T4/da active
- 2004-08-14 US US10/568,941 patent/US8980308B2/en active Active
- 2004-08-14 PL PL04764129T patent/PL1656122T5/pl unknown
- 2004-08-14 RU RU2005141214/15A patent/RU2397757C2/ru not_active IP Right Cessation
- 2004-08-14 CA CA2535063A patent/CA2535063C/en not_active Expired - Fee Related
- 2004-08-14 KR KR1020067003176A patent/KR20060065692A/ko not_active Ceased
- 2004-08-14 ES ES04764129T patent/ES2335771T5/es not_active Expired - Lifetime
- 2004-08-14 DE DE502004010303T patent/DE502004010303D1/de not_active Expired - Lifetime
- 2004-08-14 EP EP04764129A patent/EP1656122B2/de not_active Expired - Lifetime
- 2004-08-14 PT PT04764129T patent/PT1656122E/pt unknown
- 2004-08-14 MX MXPA06001815A patent/MXPA06001815A/es active IP Right Grant
- 2004-08-14 SI SI200431317T patent/SI1656122T2/sl unknown
- 2004-08-14 JP JP2006523588A patent/JP2007502795A/ja not_active Withdrawn
- 2004-08-14 AU AU2004266063A patent/AU2004266063B2/en not_active Ceased
- 2004-08-14 AT AT04764129T patent/ATE446744T1/de active
- 2004-08-14 NZ NZ545593A patent/NZ545593A/en not_active IP Right Cessation
- 2004-08-14 CN CNA2004800225495A patent/CN1832732A/zh active Pending
- 2004-08-14 BR BRPI0412054-0A patent/BRPI0412054A/pt not_active IP Right Cessation
-
2005
- 2005-12-02 ZA ZA200509779A patent/ZA200509779B/en unknown
-
2006
- 2006-02-13 IL IL173712A patent/IL173712A/en not_active IP Right Cessation
-
2011
- 2011-12-16 JP JP2011275858A patent/JP5827114B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE446744T1 (de) | Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit | |
| EA200800798A1 (ru) | Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха | |
| BRPI0418029A (pt) | formulação de anticorpos cd40 e métodos | |
| DE69803360D1 (de) | Anwendungsformen zur behandlung der männlichen erektilen dysfunktion | |
| MXPA05010873A (es) | Metodos para el tratamiento de enfermedad de parkinson. | |
| SV2002000245A (es) | Oxazolidinonas substituidas y su uso ref. lea 34122-sv | |
| NO20056132L (no) | Krystallinsk form av beta2 adrenergisk receptoragonist | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| ATE431141T1 (de) | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| CY1108794T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| GEP20053652B (en) | Salts of A Isothiazole-4-Carboxamide and their Use as Anti-Hyperproliferation Agents | |
| DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| MA26964A1 (fr) | Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase. | |
| DE602007011975D1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
| ATE413177T1 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| MXPA05006408A (es) | Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos. | |
| AR033807A1 (es) | Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y de sus sales aceptables para uso fisiologico, y las composiciones farmaceuticas que contiene estos compuestos | |
| DE602004029993D1 (de) | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit | |
| WO2020168337A4 (en) | Compositions and methods for treatment of depression and other disorders | |
| BR0313543A (pt) | 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b | |
| FR2885128B1 (fr) | Composition cosmetique a visee depigmentante ou eclaircissante comprenant au moins une oxazoline, a titre de principe actif depigmentant ou eclaircissant | |
| FR2809725B1 (fr) | Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant |